<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177602</url>
  </required_header>
  <id_info>
    <org_study_id>TARC-01</org_study_id>
    <nct_id>NCT04177602</nct_id>
  </id_info>
  <brief_title>Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial</brief_title>
  <official_title>Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Center North (CTC North GmbH &amp; Co. KG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servier Affaires Médicales</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD)
      of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1)
      with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a
      standard - calibration arm (internal control) with capecitabine CRT flanked by translational
      research in patients with locally advanced rectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter randomized seamless phase I/II trial with a phase I for determination
      of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II
      trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil in
      combination with standard radiotherapy and a standard - calibration arm (internal control)
      with capecitabine CRT flanked by translational research, designed to assess the clinical
      performance and efficacy of Trifluridine/tipiracil compared to current standard capecitabine
      chemoradiation in patients with locally advanced rectal cancer.

      The primary clinical objective in phase I is to determine the dosage and feasibility of
      Trifluridine/tipiracil based chemoradiation and in phase II whether Trifluridine/tipiracil
      with preoperative chemoradiation improves pathological complete remissions in patients with
      locally advanced rectal cancer.

      The secondary objectives are to evaluate Trifluridine/tipiracil chemoradiation with respect
      to disease free survival, overall survival, local regional failure, pathological down-staging
      (ypT0-2N0) rate, tumour regression grade, histopathological R0 resection rate, neoadjuvant
      rectal score (NAR), and perioperative complication rate. Safety and toxicity, according to
      NCI CTC AE v5, quality of life and feasibility of the regimen are further secondary
      objectives that are to be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with Trifluridine/tipiracil based chemoradiotherapy (CRT) and a standard - calibration arm (internal control) with capecitabine CRT flanked by translational research</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)/Phase 1 part</measure>
    <time_frame>8 weeks</time_frame>
    <description>Toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of pathological complete remissions (pCR)/Phase 2 part</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>4 years</time_frame>
    <description>recurrence and survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional failure</measure>
    <time_frame>4 years</time_frame>
    <description>Loco-regional recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological R0 resection rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour regression grades</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological down-staging (ypT0-2N0) rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pathohistological response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neoadjuvant rectal score (NAR)</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical stage and Pathohistological response (&lt;8 low, 8-16 intermediate, &gt;16 high risk)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of adverse events according to NCI CTC AE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of perioperative complications</measure>
    <time_frame>3 months</time_frame>
    <description>Perioperative complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Trifluridine/tipiracil based radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trifluridine/tipiracil based chemoradiotherapy (CRT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard calibration arm (internal control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capecitabine based chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Trifluridine/tipiracil chemoradiation</intervention_name>
    <description>Trifluridine/tipiracil based chemoradiation</description>
    <arm_group_label>Trifluridine/tipiracil based radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Capecitabine based chemoradiation</intervention_name>
    <description>Capecitabine based chemoradiation</description>
    <arm_group_label>standard calibration arm (internal control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients with histologically proven adenocarcinoma of the rectum
             (tumour ≤ 12 cm from the anal verge)

          2. Indication for neoadjuvant chemoradiation: clinical tumour stage T3/4 or any
             node-positive disease (clinical stage according the TNM classification system, based
             on MRI).

          3. No evidence of metastatic disease (as evidenced by negative CT-scan of the chest and
             abdomen).

          4. The disease must be considered either resectable at the time of entry or expected to
             become resectable after preoperative chemoradiation.

          5. Age ≥ 18 years

          6. WHO/ECOG Performance Status ≤ 2

          7. No prior cytotoxic chemotherapy or radiotherapy for rectal cancer.

          8. No prior radiotherapy to the pelvis, for any reason.

          9. Presence of adequate contraception in fertile patients. Adequate methods of
             contraception are: intra-uterine device, hormonal contraception, condom use with
             spermicide. Pregnant or breastfeeding women are excluded from participation.

         10. Adequate bone marrow, hepatic and renal function: Haemoglobin ≥9.0 g/dL (transfusions
             allowed to achieve or maintain levels), absolute neutrophil count ≥ 1.5 x 109/L,
             platelet count ≥ 100 x 109/L, ALAT, ASAT ≤ 2.5 x ULN, Alkaline phosphatase ≤ 2.5 x
             ULN, Total bilirubin ≤1.5 x ULN, Creatinine clearance &gt; 50 mL/min (calculated
             according to Cockroft and Gault).

         11. Ability to swallow tablets.

         12. Written informed consent and patient's agreement to comply with the study protocol.

        Exclusion Criteria:

          1. Previous (within the last 3 years) or concurrent malignancies, with the exception of
             adequately treated cone-biopsied in situ carcinoma of the cervix or basal cell
             carcinoma of the skin.

          2. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure,
             symptomatic coronary artery disease and cardiac arrhythmia not well controlled with
             medication) or myocardial infarction within the last 12 months.

          3. Known allergy or any other adverse reaction to any of the study drugs or to any
             related compound.

          4. Known significant impairment of intestinal resorption (e.g. chronic diarrhea,
             inflammatory bowel disease).

          5. Pre-existing condition which would deter chemoradiotherapy or radiotherapy, i.e.
             fistulas, severe ulcerative colitis (particularly patients currently taking
             sulphasalazine), Crohn's disease, prior adhesions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Stein</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Cancer Center Hamburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Stein</last_name>
    <phone>+49(0)403603522</phone>
    <phone_ext>0</phone_ext>
    <email>stein@hope-hamburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marianne Sinn</last_name>
    <phone>+49(0)407410</phone>
    <phone_ext>0</phone_ext>
    <email>ma.sinn@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus Hospital</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lübecker Onkologische Schwerpunktpraxis Dres. med. Uthgenannt, Kirso, Weber</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik Dr. Hancken / MVZ Onkologie</name>
      <address>
        <city>Stade</city>
        <state>Schleswig-Holstein</state>
        <zip>21680</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch- Onkologische Praxis Eppendorf (HOPE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>II. Medizinische Klinik und Poliklinik Hubertus Wald Tumorzentrum - UCCH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Sinn, Dr</last_name>
      <phone>+49(0)407410</phone>
      <phone_ext>70434</phone_ext>
      <email>ma.sinn@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Mueller</last_name>
      <phone>+49(0)7410</phone>
      <phone_ext>57725</phone_ext>
      <email>tho.mueller@uke.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis für Innere Medizin Schwerpunkt Hämatologie, Onkologie und Palliativmedizin Dres. Verpoort, Wierecky &amp; Zeller</name>
      <address>
        <city>Hamburg</city>
        <zip>20259</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch- Onkologische Praxis Altona (HOPA)</name>
      <address>
        <city>Hamburg</city>
        <zip>22767</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trifluridine tipiracil chemoradiation</keyword>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trifluridine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

